SCHEDULE: Daniel E. Stone Reports 9.99% Ownership in Scinai Immunotherapeutics Ltd.

Daniel E. Stone has reported a 9.99% beneficial ownership stake in Scinai Immunotherapeutics Ltd., primarily through American Depositary Shares and pre-funded warrants.

Summary

• Daniel E. Stone has filed a Schedule 13G, reporting beneficial ownership of 87,746 American Depositary Shares (ADS) of Scinai Immunotherapeutics Ltd.
• This represents 9.99% of the company's outstanding ordinary shares.
• The ownership includes 62,400 ADSs held directly and 25,346 ADSs issuable upon exercise of pre-funded warrants held by RK Stone Miami LLC.
• RK Stone Miami LLC holds 646,442 pre-funded warrants, but their exercise is limited to maintain beneficial ownership below 9.99%.
• Future issuances of ordinary shares or ADSs by the issuer may cause additional pre-funded warrants to become exercisable within the ownership limitation.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing indicating a significant ownership stake, which is generally positive. The structure of the warrants is also a positive sign of potential future growth.

Positives

• The filing indicates a significant ownership stake by Daniel E. Stone, suggesting confidence in the company.
• The structure of the pre-funded warrants allows for potential future increase in shareholding without exceeding the 9.99% limit.

Risks

• The exercise of pre-funded warrants is contingent on maintaining ownership below 9.99%, which could limit the potential upside for Stone.
• Future share issuances by Scinai could dilute the ownership percentage of existing shareholders.

Future Outlook

Future issuances of ordinary shares or ADSs by the issuer are expected to cause additional amounts of pre-funded warrants to become exercisable within the 9.99% ownership limitation.

Industry Context

This filing is a standard disclosure for investors who acquire a significant stake in a publicly traded company. It provides transparency regarding ownership and potential influence.

Comparison to Industry Standards

• Schedule 13G filings are common for investors holding more than 5% of a company's stock, aligning with standard regulatory practices.
• The 9.99% ownership stake is a significant position, but not unusual for institutional or large individual investors.
• The use of pre-funded warrants with ownership limitations is a common mechanism to manage ownership percentages and potential dilution.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the ownership structure of the company.
• The significant ownership stake by Daniel E. Stone could be viewed positively by the market.

Key Dates

Keywords

Scinai Immunotherapeutics, Daniel E. Stone, American Depositary Shares, ADS, Beneficial Ownership, Pre-funded Warrants, Schedule 13G, RK Stone Miami LLC